IN2014CN04927A - - Google Patents

Info

Publication number
IN2014CN04927A
IN2014CN04927A IN4927CHN2014A IN2014CN04927A IN 2014CN04927 A IN2014CN04927 A IN 2014CN04927A IN 4927CHN2014 A IN4927CHN2014 A IN 4927CHN2014A IN 2014CN04927 A IN2014CN04927 A IN 2014CN04927A
Authority
IN
India
Prior art keywords
env protein
lentiviral env
mutated lentiviral
fragment
variant
Prior art date
Application number
Inventor
Thierry Heidmann
Original Assignee
Viroxis S A S
Centre Nat Rech Scient
Univ Paris Sud Xi
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis S A S, Centre Nat Rech Scient, Univ Paris Sud Xi, Roussy Inst Gustave filed Critical Viroxis S A S
Publication of IN2014CN04927A publication Critical patent/IN2014CN04927A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising as active substance a mutated lentiviral ENV protein substantially devoid of immunosuppressive properties or a variant of said mutated lentiviral ENV protein or a fragment of the above proteins in association with a pharmaceutically acceptable carrier.
IN4927CHN2014 2011-12-07 2012-12-07 IN2014CN04927A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (1)

Publication Number Publication Date
IN2014CN04927A true IN2014CN04927A (en) 2015-09-18

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4927CHN2014 IN2014CN04927A (en) 2011-12-07 2012-12-07

Country Status (16)

Country Link
US (1) US9682137B2 (en)
EP (1) EP2788372B1 (en)
JP (2) JP6415324B2 (en)
KR (1) KR102059918B1 (en)
CN (1) CN104169295B (en)
AU (1) AU2012350258B2 (en)
BR (1) BR112014013704B1 (en)
CA (1) CA2856180C (en)
DK (1) DK2788372T3 (en)
ES (1) ES2748864T3 (en)
IL (1) IL232926B (en)
IN (1) IN2014CN04927A (en)
MX (1) MX350689B (en)
RU (1) RU2654673C2 (en)
WO (1) WO2013083799A1 (en)
ZA (1) ZA201403617B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7277466B2 (en) * 2017-09-01 2023-05-19 インプラザー エー・ペー・エス Vaccines for use in the prevention and/or treatment of disease
JP2024502658A (en) 2021-01-13 2024-01-22 ヴィロキシ Measles-HIV or measles-HTLV vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2005229411B2 (en) 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
ES2572132T3 (en) 2004-08-17 2016-05-30 Roussy Inst Gustave HIV nef mutated to modulate immunity
CA2735278A1 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
RU2426788C1 (en) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Genetic make-ups for anti-hiv therapy

Also Published As

Publication number Publication date
CN104169295A (en) 2014-11-26
AU2012350258A8 (en) 2014-07-17
EP2788372A1 (en) 2014-10-15
JP2015505836A (en) 2015-02-26
MX2014006744A (en) 2014-12-08
CN104169295B (en) 2020-07-28
RU2654673C2 (en) 2018-05-21
DK2788372T3 (en) 2019-10-14
IL232926A0 (en) 2014-07-31
CA2856180C (en) 2022-09-06
ZA201403617B (en) 2015-07-29
JP6415324B2 (en) 2018-10-31
JP2018150370A (en) 2018-09-27
RU2014127521A (en) 2016-02-10
IL232926B (en) 2019-01-31
BR112014013704A2 (en) 2021-02-17
AU2012350258B2 (en) 2017-03-02
WO2013083799A1 (en) 2013-06-13
ES2748864T3 (en) 2020-03-18
AU2012350258A1 (en) 2014-06-05
MX350689B (en) 2017-09-13
KR102059918B1 (en) 2020-02-11
EP2788372B1 (en) 2019-07-10
US9682137B2 (en) 2017-06-20
KR20140116091A (en) 2014-10-01
US20140294880A1 (en) 2014-10-02
BR112014013704B1 (en) 2023-01-31
CA2856180A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
NZ730763A (en) Methods of treating a tauopathy
CL2012003075A1 (en) Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution.
EA201270722A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
MX359288B (en) Ivabradine hydrochloride form iv.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2013004061A (en) Cyclosporin analogs.
JO3154B1 (en) Trpv4 antagonists
IL226501A (en) Protein delivery from stem cell microcarriers
EA201490427A1 (en) IVABRADIN PREPARATION OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS WITH A LOW-CUT
RU2011134931A (en) STRAIN ENTEROCOCCUS USED FOR PREPARATION OF ACID-BEVERAGE DRINKS
IN2014KN00892A (en)
MX2013004062A (en) Cyclosporin analogs.
EP2782926A4 (en) Peptide sequence design and use thereof for peptide-mediated sirna delivery
EA201492068A1 (en) PEPTID HYDROCHLORIDE SALT AND ITS APPLICATION IN COMBINATION WITH OTHER PEPTIDES IN IMMUNOTHERAPY
IN2014KN00893A (en)
EA201390955A1 (en) ROBO1-FC fusion protein for use in the treatment of hepatocarcinoma
BR112013017267A2 (en) liposome formulation, suspension and pharmaceutical composition
EA201490041A1 (en) PLASTER CONTAINING DICLOFENAC AND THYOKOLCHICOSID
WO2013190509A3 (en) Preparation of intermediates of boceprevir
WO2014039074A3 (en) Therapeutic compositions and related methods
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
EA201391643A1 (en) COMPOSITIONS WITH DELAYED PARACETAMOL DELIVERY
IN2014CN04927A (en)
EP2827896A4 (en) Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate